nor-NOHA

nor-NOHA is a selective and reversible arginase inhibitor. nor-NOHA induces apoptosis in ARG2-expressing cells under hypoxia. nor-NOHA has anti-leukemic activity. nor-NOHA can used in study of endothelial dysfunction, immunosuppression and metabolism^[1][2]. In Vitro:nor-NOHA (0.1-1 mM, 72 h) induces apoptosis in a dose-dependent manner under hypoxia (1.5% O2) in K562 cells^[1]. nor-NOHA (1 mM, 72 h) attenuates hypoxia-mediated resistance towards imatinib in K562 or KCL22 cells^[1]. In Vivo:nor-NOHA (100 mg/kg, i.v., once time) induces a significant reduction of infarct size in male Sprague-Dawley rats^[2]. nor-NOHA (100 mg/kg, i.v., once time) increases plasma citrulline and nitrite levels and decreases the ornithine plasma levels in male Sprague-Dawley rats^[2].